📇 Rhumatologue · BOULOGNE BILLANCOURT CEDEX · (92) · Hospitalier

MME NADINE ATTAL

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (3 thèses dirigées)
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 BOULOGNE BILLANCOURT CEDEX (92)HospitalierRPPS 10000474600

Enseignement

📊 Reconnaissance scientifique : 72/100📝 340 articles publiés🇫🇷 Publications académiques françaises (8)🎓 3 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial

Brain : a journal of neurology · 2021

📚 139 citations🎯 RCR 12.57Top 2% NIH🩺 Clinique

Lire l'abstract Crossref ↓

Abstract Repetitive transcranial magnetic stimulation (rTMS) has been proposed to treat neuropathic pain but the quality of evidence remains low. We aimed to assess the efficacy and safety of neuronavigated rTMS to the primary motor cortex (M1) or dorsolateral prefrontal cortex (DLPFC) in neuropathic pain over 25 weeks. We carried out a randomized double-blind, placebo-controlled trial at four outpatient clinics in France. Patients aged 18–75 years with peripheral neuropathic pain were randomly assigned at a 1:1 ratio to M1 or DLPFC-rTMS and rerandomized at a 2:1 ratio to active or sham-rTMS (10 Hz, 3000 pulses/session, 15 sessions over 22 weeks). Patients and investigators were blind to treatment allocation. The primary end point was the comparison between active M1-rTMS, active DLPCF-rTMS and sham-rTMS for the change over the course of 25 weeks (Group × Time interaction) in average pain intensity (from 0 no pain to 10 maximal pain) on the Brief Pain Inventory, using a mixed model repeated measures analysis in patients who received at least one rTMS session (modified intention-to-treat population). Secondary outcomes included other measures of pain intensity and relief, sensory and affective dimensions of pain, quality of pain, self-reported pain intensity and fatigue (patients diary), Patient and Clinician Global Impression of Change (PGIC, CGIC), quality of life, sleep, mood and catastrophizing. This study is registered with ClinicalTrials.gov NCT02010281. A total of 152 patients were randomized and 149 received treatment (49 for M1; 52 for DLPFC; 48 for sham). M1-rTMS reduced pain intensity versus sham-rTMS (estimate for Group × Session interaction: −0.048 ± 0.02; 95% CI: −0.09 to −0.01; P = 0.01). DLPFC-rTMS was not better than sham (estimate: −0.003 ± 0.01; 95% CI: −0.04 to 0.03, P = 0.9). M1-rRMS, but not DLPFC-rTMS, was also superior to sham-rTMS on pain relief, sensory dimension of pain, self-reported pain intensity and fatigue, PGIC and CGIC. There were no effects on quality of pain, mood, sleep and quality of life as all groups improved similarly over time. Headache was the most common side effect and occurred in 17 (34.7%), 23 (44.2%) and 13 (27.1%) patients from M1, DLPFC and sham groups, respectively (P = 0.2). Our results support the clinical relevance of M1-rTMS, but not of DLPFC-rTMS, for peripheral neuropathic pain with an excellent safety profile.

Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis

The Lancet. Neurology · 2025

📚 111 citations🎯 RCR 51.08🔓 Open Access

Advances and challenges in neuropathic pain: a narrative review and future directions

British journal of anaesthesia · 2023

📚 89 citations🎯 RCR 14.03Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME NADINE ATTAL

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal33

Essai clinique6

Revue générale5

Pharmacovigilance3

Revue / méta-analyse2

Épidémiologie & registres1

Génétique1

IA en rhumatologie1

Qualité de vie / PROMs1

Recommandations1

Santé mentale / fatigue1

Datasets & protocoles partagés

Partager cette fiche